2
Announcements
Trials
Browse
Landscape
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
121
Neoplasm Metastasis
12
Prostate Cancer Metastatic
4
Oligometastatic Prostate Cancer
3
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
3
Metastatic Hormone-sensitive Prostate Cancer
3
Adenocarcinoma
3
Radiation Injuries
2
Prostatic Diseases
2
Prostate CA
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Metastatic Castration-resistant Prostate Cancer
2
Urologic Diseases
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stage IV Prostate Adenocarcinoma AJCC v7
1
Stage I Prostate Adenocarcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Adenocarcinoma
1
PSA Level Greater Than 0.03
1
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Neoplasm Recurrence, Local
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-sensitive Prostate Cancer
1
Interventions
Sildenafil Citrate
9
Tadalafil
4
Surveys and Questionnaires
2
Pentoxifylline
2
Alprostadil
2
udenafil
1
trametinib
1
sotorasib
1
selpercatinib
1
pembrolizumab
1
osimertinib
1
mirabegron
1
methyl 3-mercaptopropionimidate
1
lorlatinib
1
dabrafenib
1
cemiplimab
1
brigatinib
1
bicalutamide
1
alpha-Tocopherol
1
alectinib
1
Yoga
1
Vitamin E
1
Tamoxifen
1
Tacrolimus
1
Tablets
1
Surgical Instruments
1
Saline Solution
1
Restraint, Physical
1
Psychiatric Rehabilitation
1
Preservation, Biological
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Erectile Dysfunction
×
Androgen Antagonists
×
Clear all
NCT07460726
2026-03-10
PRIAPUS-PCa
CancerCare Manitoba
Not yet recruiting
130 enrolled